*   **- Investigators:** Yes
*   **- Outcome assessors:** Yes
*   **Intention-to-treat:** Yes
*   **Follow-up period:** 12-week
*   **Loss to follow-up:** 39/570 for indacaterol+tiotropium, 35/561 for tiotropium+placebo group

| ITT anlaysis | Indacaterol+tiotropium | Placebo+tiotropium |
| :------------------------------ | :--------------------- | :----------------- |
| Number | 570 | 561 |
| Age | 64,0±9,07 | 63,4±9,22 |
| Sex (M) | 70% | 67% |
| Ethnicity (Caucasian) | 78,2 | 76,8 |
| FEV₁ %predicted (postBD)* | 48,3 (9,70) | 48,9 (11,46) |
| FEV₁/FVC (postBD)* | 46,4 (9,74) | 45,8 (10,00) |
| FEV₁ reversibility (%)\* | 16,5 (14,48) | 17,3 (17,13) |

**Inclusion**
- Aged ≥40 years
- A smoking history of ≥10 pack yrs
- A diagnosis of moderate-to-severe COPD (postbronchodilator 30≤FEV₁<65, FEV₁/FVC<0,7)

**Exclusion**
- A history of asthma
- History of exacerbation within the previous 6 weeks

**Intervention**
- Indacaterol+tiotropium: Indacaterol 150 μg once daily, Tiotropium, 18 μg once daily
- Placebo+tiotropium: Tiotropium, 18 μg once daily

### Result

| Outcome | Indacaterol+tiotropium | Placebo+tiotropium |
| :----------------------- | :--------------------- | :----------------- |
| Number | 570 | 561 |

#### Differences between indacaterol+tio vs. tio+placebo

| Outcome | Value (95% CI) |
| :---------------------------- | :--------------- |
| FEV₁ AUC 5 min~8 h | 120 mL (90~160) |
| COPD severity - moderate | 120 mL (90~150) |
| COPD severity - severe | 130 mL (100~170) |
| Smoking status - ex smoker | 120 mL (90~160) |
| Smoking status - current smoker | 130 mL (100~160) |
| ICS use - non-users | 120 mL (90~160) |
| ICS use - users | 130 mL (100~160) |

#### Trough FEV₁

| Outcome | Value (95% CI) |
| :---------------------------- | :--------------- |
| COPD severity - moderate | 90 mL (50~130) |
| COPD severity - severe | 70 mL (30~110) |
| Smoking status - ex smoker | 70 mL (40~110) |
| Smoking status - current smoker | 80 mL (40~130) |
| ICS use - non-users | 70 mL (30~110) |
| ICS use - users | 80 mL (50~120) |

#### Patient reported symptoms and use of as-needed salbutamol

| Outcome | Indacaterol+tiotropium | Placebo+tiotropium |
| :------------------------------------------ | :--------------------- | :----------------- |
| Change from baseline symptom score (full 24 h) | -2,1 (0,20) | -1,6 (0,21) |
| Change from baseline symptom score (day-time) | -1,2 (0,10) | -0,9 (0,10) |
| Change from baseline symptom score (night-time) | -1,0 (0,10) | -0,8 (0,10) |
| Change from baseline salbutamol use (puff/day) | -2,5 (0,17) | -1,3 (0,17) |
| Days during treatment with no salbutamol use (%) | 43,2 (1,91) | 34,2 (1,93) |

#### Adverse events (%)

| Outcome | Indacaterol+tiotropium | Placebo+tiotropium |
| :--------------------------- | :--------------------- | :----------------- |
| Cough | 10,4 | 3,7 |
| Muscle spasm | 2,3 | 0 |
| Plasma potassium <3,5 mmol/L | 2,3 | 2,1 |
| Systolic BP-high | 2,3 | 0,5 |
| QTc interval (absolute value) | 3,2 | 2,9 |

### PICO 및 근거표

*   **Author, year publication:** Donald A Mahler et al., 2012
*   **Title:** Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior omparad

<PAGE>122